The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer

Pathology Research and Practice

Volumn 193, Issue 11-12, 1997, Pages 767-775

  Korkolopoulou, Penelope ^a,b   Christodoulou, Panayota ^a   Kapralos, Panayotis ^a   Exarchakos, Michael ^a   Bisbiroula, Anna ^a   Hadjiyannakis, Michael ^a   Georgountzos, Constantine ^a   Thomas Tsagli, Euphemia ^a  

^a Asklepeion Hospital   (Greece)

^b NONE   (Greece)

Author keywords

c erb B 2; EGFR; KI 67; MDM2; p53; PCNA; Urinary bladder cancer

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0031409545     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(97)80055-6     Document Type: Article

References (46)

1. Barbareschi M, Girlando S, Fellini G, Graffer U, Luciani L, Dalla-Palma P (1995) Expression of MDM2 and p53 proteins in transitional cell carcinoma. Urol Res 22: 349-352
2. Berger MS, Greenfield C, Gullick WJ, Halley J, Downward J, Neal DE, Harris AL, Waterfield MD (1987) Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 56: 533-537
3. Berner A, Jacobsen A-B, Fossa SD, Nesland JM (1993) Expression of c-erb B-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder. J Pathol 22: 327-333
4. Bush C, Price P, Norton J, Parkins CS, Bailey MJ, Boyd J, Jones CR, A'Hern RPA, Horwich A (1991) Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 65: 357-360
5. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J Pathol 168: 357-363
6. Coombs LM, Oliver S, Sweeney E, Knowles M (1993) Immunocytochemical localisation of c-erb B-2 protein in transitional cell carcinoma of the urinary bladder. J Pathol 169: 35-42
7. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA (1991) Amplification and overexpression of c-erb B-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63: 601-608
8. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicier A (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353
9. Cox DR (1972) Regression models and life tables. J Roy Stat (Sect B) 34: 187-220
10. Dalbagni G, Presi JC jr, Reuter VE, Zhang ZF, Sarkis AS, Fair WR, Cordon-Cardo C (1993) Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2: 4-13
11. Esrig D, Spruck CH 3d, Nichols P, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 143: 1389-1397
12. Fosså SD, Berner AA, Jacobsen AB, Waehre H, Kvarstein B, Urnes T, Øgreid P, Bjerklund Johansen TE, Slide J, Nesland JM, Pettersen EO (1993) Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erb B-2 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer 68: 572-578
13. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O (1994) Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 86: 1331-1335
14. Hanks SK, Quinn AM, Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52
15. Krüger S, Müller H (1995) Correlation of morphometry, nucleolar organiser regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 75: 480-484
16. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis A, Reuter VE, Cordon-Cardo C (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86: 1325-1330
17. Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erb B-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125
18. Lipponen P (1993) Expression of c-erb B-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 29: 749-753
19. Lipponen PK, Eskelinen MJ (1992) Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer 66: 171-176
20. Lipponen PK (1993) Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53: 365-370
21. Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50: 2530-2537
22. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mcdiated tranvactivation. Cell 69: 1237-1245
23. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, Watanuki T, Hikage T, Katsuta N, Mori (1991) Expression of c-erb B-2 gene product in urinary bladder cancer. J Urol 145: 423-427
24. Mostofi FK, Sobin LH, Torloni H (1973) International Typing of Urinary Bladder Tumours, WHO, Geneva
25. Mulder AH, Van Hootegem JCSP, Sylvester R (1992) Prognostic factors in bladder carcinoma: Histological parameters and expression of a cell-cycle related nuclear antigen (Ki-67). J Pathol 166: 37-45
26. Munck-Wikland E, Edstrom S, Jungmark E, Kuylenstierna R, Lindholm J, Auer G (1994) Nuclear DNA content, proliferating cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. Int J Cancer 56: 95-99
27. Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas MD, Dimopoulos C (1995) Evaluation of overexpression of p53 tumour suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with DNA ploidy. Urology 46: 334-340
28. Nakopoulou L, Zervas A, Constantinides C, Deliveliotis C, Stefanaki K, Dimopoulos C (1995) Epithelial differentiation antigens and epidermal growth factor receptors in transitional cell bladder carcinoma: Correlation with prognosis. Urol Int 54: 191-197
29. Neal DE, Sharpers L, Smith K, Fennely J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625
30. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J, Niehans GA (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101: 166-176
31. Norton AJ, Jordan S, Yeomans P (1994) Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173: 371-379
32. Pryor JP (1973) Factors influencing the survival of patients with transitional cell tumours of the urinary bladder. Br J Urol 45: 586-591
33. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhany ZF, Sheinjeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53-59
34. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K. Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, Kato T (1992) An immunohistologic evaluation of c-erb B-2 gene product in patients with urinary bladder carcinoma. Cancer 70: 2493-2498
35. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709
36. Skopelitou A, Alexopoulou V, Dimopoulos D, Hadjiyannakis M, Rigas C, Kamina S, Krikoni O, Agnantis NJ (1996) p53 and c-jun expression in urinary bladder transitional cell carcinoma. Correlation with proliferating cell nuclear antigen (PCNA), histological grade and clinical stage. Eur Urol (to be published)
37. Skopelitou A, Korkolopoulou P, Papanikolaou A, Christodoulou P, Thomas-Tsagli E, Pavlakis K (1992) Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organiser region staining in transitional cell carcinomas of the urinary bladder. Eur Urol 22: 235-240
38. Smith K, Fennelly JA, Neal DE, Hall PR, Harris AL (1989) Characterisation and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumours. Cancer Res 49: 5810-5814
39. Soini Y, Turpeenniemi-Hujonen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nworva K, Pääkkö P, Vähäkangas K (1993) p53 immunohistochemistry in transitional cell carcinomas and dysplasia of the urinarybladder correlates with disease progression. Br J Cancer 68: 1029-1035
40. Stavropoulos NE, Joachim-Velogianni E, Hjastazeris K, Kitsiou E, Stefanaki S, Agnantis N (1993) Growth fractions in bladder cancer defined by Ki67-association with cancer grade category and recurrence rate of superficial lesions. Br J Urol 72: 736-739
41. UICC (1978) TNM classification of malignant tumours (2rd ed.). UICC, Geneva
42. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523-526
43. Wood DP jr, Wartinger DD, Reuter V, Cordon-cardo C, Fair WR, Chaganti RSK (1991) DNA, RNA and immunohistochemical characterisations of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J Urol 146: 1398-1401
44. Wright C, Mellon K, Johnston P, Land DP, Harris AL, Home CHN, Neal DE (1991) Expression of mutant p53, c-erb B2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63: 967-970
45. Zhau HE, Zhang X, von Eschenbach AC, et al (1990) Amplification and expression of the c-erb B-2/neu protoontogene in human bladder cancer. Mol Carcinogen 3: 257-257
46. Zingg EJ, Wallace DMA (1986) Clinical practice in urology. Bladder cancer. Springer Verlag